Literature DB >> 21044954

Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells.

Fionnuala Ní Ainle1, James S O'Donnell, Jennifer A Johnson, Laura Brown, Eimear M Gleeson, Owen P Smith, Roger J S Preston.   

Abstract

Activated protein C (APC) has potent anticoagulant and anti-inflammatory properties that limit clot formation, inhibit apoptosis, and protect vascular endothelial cell barrier integrity. In this study, the role of N-linked glycans in modulating APC endothelial cytoprotective signaling via endothelial cell protein C receptor/protease-activated receptor 1 (PAR1) was investigated. Enzymatic digestion of APC N-linked glycans (PNG-APC) decreased the APC concentration required to achieve half-maximal inhibition of thrombin-induced endothelial cell barrier permeability by 6-fold. Furthermore, PNG-APC exhibited increased protection against staurosporine-induced endothelial cell apoptosis when compared with untreated APC. To investigate the specific N-linked glycans responsible, recombinant APC variants were generated in which each N-linked glycan attachment site was eliminated. Of these, APC-N329Q was up to 5-fold more efficient in protecting endothelial barrier function when compared with wild type APC. Based on these findings, an APC variant (APC-L38D/N329Q) was generated with minimal anticoagulant activity, but 5-fold enhanced endothelial barrier protective function and 30-fold improved anti-apoptotic function when compared with wild type APC. These data highlight the previously unidentified role of APC N-linked glycosylation in modulating endothelial cell protein C receptor-dependent cytoprotective signaling via PAR1. Furthermore, our data suggest that plasma β-protein C, characterized by aberrant N-linked glycosylation at Asn-329, may be particularly important for maintenance of APC cytoprotective functions in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044954      PMCID: PMC3020740          DOI: 10.1074/jbc.M110.159475

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Activated protein C variants with normal cytoprotective but reduced anticoagulant activity.

Authors:  Laurent O Mosnier; Andrew J Gale; Subramanian Yegneswaran; John H Griffin
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

2.  Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin.

Authors:  B W Grinnell; J D Walls; B Gerlitz
Journal:  J Biol Chem       Date:  1991-05-25       Impact factor: 5.157

3.  Permanent cell line expressing human factor VIII-related antigen established by hybridization.

Authors:  C J Edgell; C C McDonald; J B Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

4.  The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V.

Authors:  F J Walker; P W Sexton; C T Esmon
Journal:  Biochim Biophys Acta       Date:  1979-12-07

5.  Beta protein C is not glycosylated at asparagine 329. The rate of translation may influence the frequency of usage at asparagine-X-cysteine sites.

Authors:  J P Miletich; G J Broze
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

6.  The 2.8 A crystal structure of Gla-domainless activated protein C.

Authors:  T Mather; V Oganessyan; P Hof; R Huber; S Foundling; C Esmon; W Bode
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

7.  Compound heterozygous protein C deficiency resulting in the presence of only the beta-form of protein C in plasma.

Authors:  P Simioni; M Kalafatis; D S Millar; S C Henderson; S Luni; D N Cooper; A Girolami
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

8.  Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity.

Authors:  P J Fay; T M Smudzin; F J Walker
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

9.  Characterization of a cDNA coding for human protein C.

Authors:  D Foster; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Characterization and novel purification of recombinant human protein C from three mammalian cell lines.

Authors:  S C Yan; P Razzano; Y B Chao; J D Walls; D T Berg; D B McClure; B W Grinnell
Journal:  Biotechnology (N Y)       Date:  1990-07
View more
  10 in total

Review 1.  Protein C anticoagulant and cytoprotective pathways.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 2.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

3.  C-terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities.

Authors:  Atsuki Yamashita; Yuqi Zhang; Michel F Sanner; John H Griffin; Laurent O Mosnier
Journal:  J Thromb Haemost       Date:  2020-03-05       Impact factor: 5.824

4.  Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.

Authors:  Disha M Gandhi; Mark W Majewski; Ricardo Rosas; Kaitlin Kentala; Trevor J Foster; Eric Greve; Chris Dockendorff
Journal:  Bioorg Med Chem       Date:  2018-04-06       Impact factor: 3.641

5.  Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays.

Authors:  Qiulan Ding; Likui Yang; Peyman Dinarvand; Xuefeng Wang; Alireza R Rezaie
Journal:  Blood       Date:  2015-02-04       Impact factor: 22.113

6.  Interleukin-1β-induced autophagy-related gene 5 regulates proliferation of embryonic stem cell-derived odontoblastic cells.

Authors:  Nobuaki Ozeki; Naoko Hase; Taiki Hiyama; Hideyuki Yamaguchi; Rie Kawai; Ayami Kondo; Toru Matsumoto; Kazuhiko Nakata; Makio Mogi
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

7.  Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.

Authors:  Anna P Andreou; Maria Efthymiou; Yao Yu; Helena R Watts; Faruq H Noormohamed; Daqing Ma; David A Lane; James T B Crawley
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

8.  Purification of protein C from canine plasma.

Authors:  Valerie M Wong; Dorothee Bienzle; M Anthony Hayes; Paul Taylor; R Darren Wood
Journal:  BMC Vet Res       Date:  2014-10-18       Impact factor: 2.741

Review 9.  Protein C Pathway in Paediatric and Neonatal Sepsis.

Authors:  Hassan Eliwan; Murwan Omer; Ellen McKenna; Lynne A Kelly; Beatrice Nolan; Irene Regan; Eleanor J Molloy
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418

10.  Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin.

Authors:  Sonia Aguila; Irene Martínez-Martínez; Gilda Dichiara; Ricardo Gutiérrez-Gallego; José Navarro-Fernández; Vicente Vicente; Javier Corral
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.